Clinical trials: Men
Healthy
A Study in Healthy Men to Test How Well Different Doses of BI 1569912 Are Tolerated
The main objectives of this trial are to investigate (1) safety, tolerability, pharmacokinetics and pharmacodynamics following multiple rising doses of BI 1569912; (2) tolerability of BI 1569912 in an up-titrating dosing scheme.
- Trial name
- NCT04978506
- Testing
- BI 1569912
- Where
- Germany
- Volunteers
- 83 people, healthy volunteers welcome
- Sponsor
- Boehringer Ingelheim
Overactive Bladder
Extension Study of Vibegron in Men With Overactive Bladder (OAB) Symptoms on Pharmacological Therapy for Benign Prostatic Hyperplasia
This study will assess the long-term safety of vibegron when dosed up to 52 weeks in men with overactive bladder (OAB) symptoms on pharmacological therapy for Benign Prostatic Hyperplasia (BPH) who previously completed treatment…
- Trial name
- NCT04103450
- Testing
- Vibegron
- Where
- 35 sites in United States, Poland
- Volunteers
- 276 people
- Sponsor
- Urovant Sciences GmbH
Male Hypogonadism
Safety and Efficacy Trial of Oral Testosterone Undecanoate (TU) in Hypogonadal Men
The purpose of this study is to determine the safety and efficacy of an oral testosterone undecanoate formulation for use as testosterone-replacement therapy in men with low testosterone.
- Trial name
- NCT01403116
- Testing
- Oral testosterone undecanoate, topical testosterone gel
- Where
- 30 sites in United States, Germany
- Volunteers
- 325 people
- Sponsor
- Clarus Therapeutics, Inc.
Male Osteoporosis
The Effect Of Oral Ibandronate In Male Osteoporosis
Male osteoporosis is a common and important clinical problem, associated with significant morbidity, mortality and societal expense. Approximately 10% of men =65 years of age are osteoporotic.
- Trial name
- STRONG (NCT00397839)
- Testing
- Ibandronate
- Where
- 41 sites in United States
- Volunteers
- 135 people
- Sponsor
- Hoffmann-La Roche
Prostate Cancer Metastatic
Early Switch From First-Line Docetaxel/Prednisone to Cabazitaxel/Prednisone and the Opposite Sequence, Exploring Molecular Markers in Men With Metastatic Castration-Resistant Prostate Cancer (mCRPC)
Docetaxel and cabazitaxel are cancer chemotherapy agents of the taxane drug class. The purpose of this study is to explore the benefit, for treatment of metastatic castration-resistant prostate cancer (mCRPC), of a regimen in…
- Trial name
- TAXYNERGY (NCT01718353)
- Testing
- DOCETAXEL (XRP6976), CABAZITAXEL (XRP6258), Prednisone
- Where
- 19 sites in United States, Canada
- Volunteers
- 63 people
- Sponsor
- Sanofi
Erectile Dysfunction, Metabolic Syndrome
Study of Vardenafil in Patients Suffering From Erectile Dysfunction and Metabolic Syndrome
This is a controlled, randomized, multi-center prospective study of vardenafil to determine efficacy on Erectile Dysfunction (ED), tolerability and safety in men with ED and Metabolic Syndrome.
- Trial name
- NCT00738400
- Testing
- Vardenafil (Levitra, BAY38-9456)
- Where
- 19 sites in Germany
- Volunteers
- 150 people
- Sponsor
- Bayer
Hypogonadism, Male
Efficacy and Safety of Oral Testosterone Undecanoate in Hypogonadal Men
This will be a randomized, multicenter, open-label, active-controlled, efficacy, and safety study in adult hypogonadal men. The study duration is 12 months (365 days), including a 90-day, open-label efficacy period and a 9-month…
- Trial name
- NCT03198728
- Testing
- SOV2012-F1, AndroGel
- Where
- 36 sites in United States
- Volunteers
- 314 people
- Sponsor
- Marius Pharmaceuticals
Inflammation
A Study of Tomato Products and Disease Risk
The purpose of this research study is to test whether certain compounds in tomatoes will help reduce factors in the subject's blood associated with disease risk.
- Trial name
- TOM (NCT00966550)
- Testing
- Tomato, Non-tomato
- Where
- United States
- Volunteers
- 25 people, healthy volunteers welcome
- Sponsor
- Clinical Nutrition Research Center, Illinois Institute of Technology
Prostate Cancer Metastatic
Study of VERU-944 to Ameliorate Hot Flashes in Men With Advanced Prostate Cancer
Randomized, double-blind, placebo controlled, dose finding Phase 2 study comparing oral daily dosing of VERU-944 after a week of loading (daily dosing) with placebo to ameliorate the vasomotor symptoms resulting from androgen…
- Trial name
- NCT03646162
- Testing
- Veru-944
- Where
- 24 sites in United States
- Volunteers
- 93 people
- Sponsor
- Veru Inc.
Male Pattern of Hair Loss, Androgenic Alopecia
Minoxidil 5% / Botanical Hair Regimen in Men With Thinning Hair and Male Pattern Hair Loss/Androgenic Alopecia
The purpose of this study is to characterize the effect of Minoxidil 5% Foam and Botanical Hair Solution Regimen in men with thinning hair and male pattern hair loss/androgenic alopecia (Norwood III \& IV).
- Trial name
- NCT02460289
- Testing
- Treatment: Minoxidil 5% / Botanical Hair Solution for Men
- Where
- United States
- Volunteers
- 63 people
- Sponsor
- Galderma R&D
Overactive Bladder
Study to Evaluate the Efficacy, Safety and Tolerability of Vibegron in Men With Overactive Bladder (OAB) Symptoms on Pharmacological Therapy for Benign Prostatic Hyperplasia (BPH)
This study will assess the efficacy of vibegron compared with placebo in men with overactive bladder (OAB) symptoms on pharmacological therapy for benign prostatic hyperplasia (BPH) as defined by micturition and urgency episodes.
- Trial name
- NCT03902080
- Testing
- Vibegron
- Where
- 140 sites in United States, Belgium and 6 more
- Volunteers
- 1,105 people
- Sponsor
- Urovant Sciences GmbH
Healthy
A Study in Healthy Men to Find Out How Well Different Doses of BI 764122 Are Tolerated and Whether Food Affects the Amount of BI 764122 in the Blood
The main objectives of this trial are to investigate safety, tolerability and pharmacokinetics (PK) of BI 764122 in healthy male subjects following oral administration of single rising doses.
- Trial name
- NCT03794323
- Testing
- BI 764122
- Where
- Belgium
- Volunteers
- 76 people, healthy volunteers welcome
- Sponsor
- Boehringer Ingelheim
Prostatic Hyperplasia
Study to Compare the Efficacy and Safety of Combination Treatment With Dutasteride and Tamsulosin With Tamsulosin Monotherapy, in Men With Moderate to Severe Benign Prostatic Hyperplasia
This is a multicentre, randomised, double-blind, parallel group study in Asian subjects. The aim of the study is to investigate whether combination therapy with dutasteride and tamsulosin is more effective than tamsulosin…
- Trial name
- NCT02058368
- Testing
- Dutasteride 0.5mg capsules, Tamsulosin 0.2mg tablets
- Where
- 46 sites in China, Japan and 2 more
- Volunteers
- 607 people
- Sponsor
- GlaxoSmithKline
Healthy
This Study in Healthy Men Tests How Different Doses of BI 894416 Are Taken up in the Body and How Well BI 894416 is Tolerated
This first-in man trial is designed to investigate the safety and tolerability of BI 894416 in healthy male subjects following oral administration of single rising doses.
- Trial name
- NCT03315936
- Testing
- BI 894416
- Where
- Germany
- Volunteers
- 68 people, healthy volunteers welcome
- Sponsor
- Boehringer Ingelheim
Healthy
A Study to Test How Well Healthy Men Tolerate Different Doses of BI 706321
The main objectives are: Part I: To investigate safety, tolerability, and pharmacokinetics (PK) of BI 706321 in healthy male subjects following oral administration of single rising doses.
- Trial name
- NCT03971695
- Testing
- BI 706321
- Where
- Germany
- Volunteers
- 73 people, healthy volunteers welcome
- Sponsor
- Boehringer Ingelheim
Advanced Breast Cancer
Study to Assess the Safety of Alpelisib Plus Fulvestrant, in Men and Post-menopausal Women With HR-positive, HER2-negative, Advanced Breast Cancer (aBC) With PIK3CA Mutation, Whose Disease Progressed on or After Endocrine Treatment
The purpose of this study was to determine the safety of alpelisib plus fulvestrant in men and post-menopausal women with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative, advanced or…
- Trial name
- ALPINIST (NCT05631795)
- Testing
- Alpelisib, Fulvestrant
- Where
- 12 sites in India
- Volunteers
- 40 people
- Sponsor
- Novartis Pharmaceuticals
Benign Prostatic Hyperplasia
Study to Treat Patients Who Have Signs and Symptoms of Benign Prostatic Hyperplasia (BPH) With Tadalafil Daily
The purpose of this study is to determine whether an experimental drug known as tadalafil given once daily can reduce the symptoms associated with Benign Prostatic Hyperplasia (straining, urinary frequency, feeling like your…
- Trial name
- NCT00827242
- Testing
- tadalafil
- Where
- 27 sites in United States, Argentina and 3 more
- Volunteers
- 325 people
- Sponsor
- Eli Lilly and Company
Hypogonadism
The Effect of Testosterone Topical Solution (LY900011) in Hypogonadal Men With Suboptimal Response to a Topical Testosterone Gel
This study will evaluate if testosterone solution can raise testosterone hormone levels into the normal range after treatment for up to 9 Weeks, in those participants with a documented history of subtherapeutic levels [total…
- Trial name
- NCT01893281
- Testing
- Topical Testosterone Solution
- Where
- 21 sites in United States
- Volunteers
- 78 people
- Sponsor
- Eli Lilly and Company
Osteoporosis
A Study for Patients With Osteoporosis
The purpose of this study is to compare the effect of injectable teriparatide to intranasal salmon calcitonin on lumbar spine bone mineral density, in the treatment of Chinese patients with established osteoporosis
- Trial name
- NCT00414973
- Testing
- Teriparatide, Salmon Calcitonin
- Where
- 5 sites in China
- Volunteers
- 364 people
- Sponsor
- Eli Lilly and Company
Prostate Cancer
A Study to Evaluate the Safety and Efficacy of Relugolix in Men With Advanced Prostate Cancer
The purpose of this study is to determine the efficacy and safety of relugolix 120 milligrams (mg) orally once daily for 48 weeks on maintaining serum testosterone suppression to castrate levels (< 50 nanograms/deciliter [ng/dL])…
- Trial name
- HERO (NCT03085095)
- Testing
- Relugolix, Leuprolide Acetate
- Where
- 162 sites in United States, Australia and 20 more
- Volunteers
- 1,134 people
- Sponsor
- Myovant Sciences GmbH